Sonic Healthcare Limited · ASX:SHL
Sonic Healthcare — Shareholder Meeting (November 2025)
33 slides from Sonic Healthcare's shareholder meeting presentation, Nov 20, 2025
Slide 1: 2025 Annual General Meeting - CEO Presentations and Proxy Voting Summary
20 November 2025 The Manager – Listings Australian Securities Exchange Limited Level 27 39 Martin Place SYDNEY NSW 2000 Via electronic lodgement Dear Sir / Madam 2025 ANNUAL GENERAL MEETING - CEO PRESENTATIONS AND PROXY VOTING SUMMARY Dr Colin Goldschmidt, retiring Chief Executive Officer, and Dr Ji
Slide 2: Annual General Meeting
Annual General Meeting 20 November 2025
Slide 3: 2025 AGM – Summary of direct and proxy votes received before the AGM
2025 AGM – Summary of direct and proxy votes received before the AGM RESOLUTION FOR AGAINST OPEN ABSTAIN 1 Professor Christine Bennett 266,556,766 10,403,538 2,786,721 119,988 Re-election as Director (95.29%) (3.72%) 2 Dr Katharine Giles 266,554,809 10,357,599 2,848,227 106,378 Re-election as Direct
Slide 4: CEO Presentation
Annual General Meeting 20 November 2025 CEO Presentation Dr Colin Goldschmidt
Slide 5: Forward-looking Statements
Forward-looking Statements This presentation may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on f
Slide 6: FY 2026 Guidance Update
FY 2026 Guidance Update EBITDA guidance reaffirmed after 4 months’ trading EBITDA A$1.87 – 1.95 billion (constant currency) Guidance reflects up to ~13% EBITDA growth on FY 2025 (constant currency) H1 weighting FY 2026 forecast H1 weighting approximately 45-46% of full year, consistent wit
Slide 7: FY 2026 Guidance Update
FY 2026 Guidance Update Changes to depreciation and interest expense guidance Depreciation expense (including on leased assets) forecast to be A$780 – 790 million (constant currency), a lower % of revenue than previously forecast (adjusted post-LADR acquisition and 4 months’ trading) Forecast
Slide 8: Headlines FY 2025
Headlines FY 2025 A$M FY 2025 FY 2024* Change (Statutory) Revenue 9,645 8,967 8% EBITDA 1,725 1,602 8% Net profit 514 479 7% Cash generated from operations 1,297 1,072 21% Earnings per share (A$ cents) 106.7 100.4 6% EBITDA earnings guidance achieved Organic revenue growth 5% * FY 2024 numbers r
Slide 9: FY 2025 Revenue Split
FY 2025 Revenue Split SCS/Other A$465M 5% NZ A$30M Radiology A$970M 10% USA Belgium A$2,110M A$152M 22% 2% UK A$796M Total Revenue A$9,645 million (including A$22 8% million interest) SCS / Other = Sonic Clinical Services (IPN Australia Medical Centres, Sonic HealthPlus, other clinical Switzerland s
Slide 10: Capital Management
Capital Management 30 June 30 June Debt Cover History 2025 2024 3.5 Net interest-bearing debt A$M 2,818 2,349 3.0 Equity A$M 8,473 8,075 2.5 Debt cover X 2.1 1.9 2.0 Ratio (X) Gearing ratio % 24.7 22.3 1.5 Pre-pandemic average Interest cover X 10.1 12.0 1.0 0.5 Debt and equity movements impacted b
Slide 11: Dividends
Dividends Annual Dividend History A$ FY 2025 FY 2024 Growth $1.10 Interim Dividend $0.44 $0.43 2% $1.00 $0.90 Final Dividend $0.63 $0.63 0% $0.80 Total Dividends $1.07 $1.06 1% $0.70 $0.60 A$ $0.50 $0.40 Final dividend franked to 35% $0.30 Future earnings growth expected to support progressive d
Slide 12: Acquisition of LADR Laboratory Group (Germany)
Acquisition of LADR Laboratory Group (Germany) Major growth milestone for Sonic´s 20-year presence in Germany, integrating one of the other “Top 5” national groups into Sonic Healthcare Germany CY 2024 annual revenue ~€370 million, EBITDA ~€50 million Enterprise value €423 million funded in pa
Slide 13: Sustainability
Sustainability FY 2025 performance highlights ENVIRONMENT OUR PEOPLE COMMUNITIES GOVERNANCE 27% 40% 99% 129 million ✓ Reduction in scope Hybrid/electric motor Staff with access to Patient consultations Comprehensive audit of all 1 and 2 (market-based) vehicles in global fleet Employee Assistance ext
Slide 14: Sustainability
Sustainability Scope 1 and 2 (market-based) emissions and progress towards 2030 target 140,000 22.6% 120,000 reduction on 27.3% FY2030 target FY2021 base reduction on 43% reduction in year FY2021 base scope 1 and 2 year (market-based) Scope 2 emissions (tCO2-e) 100,000 emissions on FY2021 base year
Slide 15: Sustainability
Sustainability sonichealthcare.com/sustainability Independent ESG ratings during FY 2025 Prime (B-) Leader (AA) Awareness (C) Sonic Healthcare | 2025 Annual General Meeting 14
Slide 16: Thank You
Sy SONIC SY HEALTHCARE Thank You
Slide 17: The Sonic Healthcare Difference
The Sonic Healthcare Difference A World-Leading Value Proposition Dr Jim Newcombe Incoming CEO / Managing Director 20 November 2025
Slide 18: About me
About me Medical leader with strong commercial background Pathologist & infectious diseases physician - Australian-trained - Completed US Medical Licensing Examination Eight years with Sonic Healthcare CEO of Douglass Hanly Moir Pathology, Sydney - Largest Australian clinical and anatomical pa
Slide 19: Sonic Healthcare's value proposition
Sonic Healthcare’s value proposition Sonic Healthcare delivers high-value medicine – high-value medicine drives growth and financial performance. Sonic Healthcare | 2025 Annual General Meeting 18
Slide 20: Sonic Healthcare's value proposition
Sonic Healthcare’s value proposition 1. Delivery of high-value medicine - Medical Leadership – attracts staff, doctors and patients - Global reach – millions of people served each year - Highest quality medicine – leader in specialised diagnostics, delivered at scale, providing a critical community
Slide 21: Sonic Healthcare delivers high-value medicine
Sonic Healthcare delivers high-value medicine
Slide 22: Medical Leadership
Medical Leadership Our Culture Customers: People: Shareholders: The natural trend Working in a Passionate staff towards the truly medical and loyal highest quality of practice has a customers create service and higher purpose long-term patient care and attracts the shareholder builds trust and best
Slide 23: Medical Leadership
Medical Leadership Our Culture Sonic Healthcare | 2025 Annual General Meeting 22
Slide 24: Sonic's Global People
Sonic’s Global People Caring for our communities Sonic Healthcare | 2025 Annual General Meeting 23
Slide 25: Global presence
Global presence FY2025 USA Australia Pathology/laboratory medicine Pathology/laboratory medicine Revenue A$2,110M Radiology Clinical services Employees ~7,800 Revenue A$3,545M Employees ~19,600 UK Belgium Switzerland Germany New Zealand Pathology/laboratory medicine Pathology/laboratory medicine Pat
Slide 26: Sonic Healthcare delivers high-quality medicine at scale
Sonic Healthcare delivers high-quality medicine at scale Market leader through medical excellence Personalised, precision pathology - GynaePath – leading specialist women’s health provider in Australia Leader in highly specialised diagnostics - Medical Laboratory Bremen – advanced esoteric diagn
Slide 27: Sonic Healthcare is a leader in cancer diagnostics
Sonic Healthcare is a leader in cancer diagnostics Cancer is highest disease group for health system spending Diagnosis Treatment Subspecialised Anatomical Pathology (e.g. Sonic Uro Dx) IPN Medical Centres Australian PathologyWatch Skin Cancer Clinics Cancer Gene testing (e.g. HSL Advanced Diagnosti
Slide 28: High-value medicine drives growth and financial performance
High-value medicine drives growth and financial performance
Slide 29: Sonic Healthcare is growing strongly
Sonic Healthcare is growing strongly Revenue history 10 9 8 7 6 A$ billions 5 4 3 COVID 2 International 1 Australia 0 Financial year Sonic Healthcare | 2025 Annual General Meeting 28
Slide 30: Sonic Healthcare has strong growth drivers
Sonic Healthcare has strong growth drivers Organic growth - Cornerstone of modern medical practice nationally critical infrastructure - Ageing populations with increased chronic & complex healthcare needs - New & expanding markets - Medically guided customer – Mein Direktlabor, TDL Tinies - Pers
Slide 31: Focused on earnings growth
Focused on earnings growth Medical excellence & scale are driving efficiencies Strong focus on growing earnings per share and return on invested capital Targeted cost base control and innovation - Laboratory automation - Digital pathology & AI - Benchmarking and standardisation Dedicated integ
Slide 32: Summary
Summary Sonic Healthcare is a world-leading value proposition Sonic Healthcare is a world leader in high-value medicine High-value medicine drives shareholder value by: - Attracting staff, referring doctors and patients - Placing Sonic at the forefront of innovation - Increasing high-value speci
Slide 33: Thank you
SONIC HEALTHCARE Thank you
Sonic Healthcare — Shareholder Meeting (November 2025) on 6ix